Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275339 | 0.82 | CYP1A2 (0.32) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL9864225 | 0.80 | CYP2D6 (0.46) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL16335334 | 0.79 | ALDH1A1 (0.55) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL5306707 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1955 | 0.78 | ESR1 (0.53) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL29816355 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL446690 | 0.77 | CYP2D6 (0.50) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL9389474 | 0.77 | ESR1 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL2575993 | 0.77 | CYP2D6 (0.50) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL264866 | 0.75 | HCAR2 (0.58) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003389-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | The Trustees Of Columbia University In The City Of New York (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021016361-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2019018647-A1 | ANTI-GD3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | PFIZER INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| CN-106995493-A | Catilan polypeptide and conjugate and its application | 摩尔弗泰克有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3087182-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | Memorial Sloan Kettering Cancer Center (US) | 2016-11-02 | — | — | EP | disclosed |
| CN-102844044-B | Chlorotoxin polypeptides and conjugates and uses thereof | 摩尔弗泰克有限公司 | 2016-10-26 | — | — | CN | disclosed |
| WO-2015100113-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2013036755-A1 | ETV1 ANTIBODIES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013016662-A1 | DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2300045-A1 | TREATMENT OF METASTATIC TUMORS | Transmolecular, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009140599-A1 | TREATMENT OF METASTATIC TUMORS | TRANSMOLECULAR, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-0317956-A2 | Anti-tumor prodrugs | Bristol-Myers Squibb Company (US) | 1989-05-31 | — | — | EP | disclosed |